# Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

> **NCT05211986** · PHASE1,PHASE2 · RECRUITING · sponsor: **Immunis, Inc.** · enrollment: 28 (estimated)

## Conditions studied

- Muscle Atrophy

## Interventions

- **DRUG:** IMM01-STEM

## Key facts

- **NCT ID:** NCT05211986
- **Lead sponsor:** Immunis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-13
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05211986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05211986, "Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05211986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*